BACE1 and Alzheimer disease: Furthermore, in vivo studies have demonstrated that resveratrol decreases amyloid plaque formation, Aβ42 levels, BACE1 and APP levels in Tg6799 mice expressing five familial AD mutations (5xFAD mice) [140] and decreases the amount of insoluble Aβ in the hippocampus of AD rats [141].